Acetylcholinesterase inhibitors in cognitive impairment in Huntington’s disease: A brief review

Table 1 Trials and reports of Acetylcholinesterase use in Huntington’s disease

Ref.	Design	Medication used	Outcome measures	Result
Fernandes et al[11]	Open labelled study	Donepezil	UHDRS, MMSE, Wechsler memory scale-III, Symbol Digit, Odd Man Out test, Hopkins Verbal Learning test	No statistical significance between mean scores at baseline and 6 wk on all neuropsychological tests.
Rot et al[12]	Longitudinal study	Rivastigmine	UHDRS, MMSE, Trail making test	Improvement on cognitive tests and behavioural part of UHDRS
Petrikis et al[13]	Case report	Galantamine	PANSS ESRS MMSE	Improvement on PANSS and ESRS but no improvement on MMSE
de Tommaso et al[14]	Prospective, open labelled randomized controlled trial	Rivastigmine	MMSE, Marsden and Quinn Chorea Severity Scale, Total Functional Capacity score, Abnormal Involuntary Movement scale	Improvement on MMSE compared to baseline
Cubo et al[15]	Randomized controlled trial	Donepezil	UHDRS, Alzheimers Disease Assessment Scale, Sickness Impact Profile	No significant improvement except for improvement on UHRDS-FAS (Verbal Fluency test)
de Tommaso et al[16]	Randomized, blinded, controlled, open labelled prospective	Rivastigmine	MMSE, Marsden and Quinn Chorea Severity scale, Total Functional Capacity score, Abnormal Involuntary Movement scale	Slight increase in MMSE but not statistically significant

UHDRS: Unified Huntington’s Disease Rating Scale; MMSE: Mini Mental State Examination; PANSS: Positive and negative syndrome scale; ESRS: Extrapyramidal symptom rating scale.